Fifth Third Bancorp grew its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 233.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,700 shares of the company’s stock after acquiring an additional 6,089 shares during the period. Fifth Third Bancorp’s holdings in IDEXX Laboratories were worth $3,420,000 as of its most recent SEC filing.
Other hedge funds also recently modified their holdings of the company. Conning Inc. lifted its holdings in IDEXX Laboratories by 2.1% in the third quarter. Conning Inc. now owns 1,228 shares of the company’s stock worth $483,000 after acquiring an additional 25 shares during the last quarter. CSat Investment Advisory L.P. raised its holdings in shares of IDEXX Laboratories by 6.3% during the second quarter. CSat Investment Advisory L.P. now owns 454 shares of the company’s stock valued at $150,000 after buying an additional 27 shares during the last quarter. Clarius Group LLC raised its holdings in shares of IDEXX Laboratories by 2.8% during the third quarter. Clarius Group LLC now owns 1,014 shares of the company’s stock valued at $399,000 after buying an additional 28 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of IDEXX Laboratories by 10.0% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 493 shares of the company’s stock valued at $194,000 after acquiring an additional 45 shares during the period. Finally, Boston Financial Mangement LLC increased its stake in shares of IDEXX Laboratories by 2.2% during the second quarter. Boston Financial Mangement LLC now owns 2,183 shares of the company’s stock valued at $721,000 after acquiring an additional 47 shares during the period. 87.01% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ IDXX opened at $464.29 on Friday. IDEXX Laboratories, Inc. has a twelve month low of $168.65 and a twelve month high of $485.00. The company has a debt-to-equity ratio of 1.93, a quick ratio of 1.24 and a current ratio of 1.65. The stock has a market cap of $39.60 billion, a price-to-earnings ratio of 80.89, a PEG ratio of 4.92 and a beta of 0.90. The firm’s 50 day moving average price is $428.90 and its two-hundred day moving average price is $365.10.
In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 5,206 shares of IDEXX Laboratories stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $469.31, for a total transaction of $2,443,227.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Giovani Twigge sold 7,316 shares of IDEXX Laboratories stock in a transaction on Monday, August 31st. The shares were sold at an average price of $388.19, for a total transaction of $2,839,998.04. Following the sale, the vice president now directly owns 14,222 shares of the company’s stock, valued at approximately $5,520,838.18. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 103,990 shares of company stock worth $46,661,634. Corporate insiders own 2.53% of the company’s stock.
A number of research firms recently commented on IDXX. BidaskClub upgraded shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, October 21st. Credit Suisse Group lifted their price target on shares of IDEXX Laboratories from $415.00 to $422.00 and gave the stock an “outperform” rating in a research report on Monday, August 17th. Finally, Stifel Nicolaus lifted their price target on shares of IDEXX Laboratories from $280.00 to $375.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $369.25.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Further Reading: What defines an oversold asset?
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.